Key Highlights

● CME closed at $280.56 on 9 October 2026, and the second data set's $289.06 mean target implies upside of about 3.0%.

● Market data shows a higher $292.06 consensus from 18 analysts, with targets from $230 to $349.

● Market data shows nine Buy, six Hold and three Sell ratings, a Hold consensus.

● Morgan Stanley raised its target to $337 from $330 on 9 October, and Barclays, TD Cowen and UBS also raised targets in the first week of October.

CME Group Inc. (NASDAQ:CME) operates derivatives exchanges and is a member of the S&P 500. The shares closed at $280.56 on Friday 9 October 2026, with the average analyst target only about 3% higher.

What Is the Latest Analyst Price Target?

The second data set reports a mean target of $289.06 and a median of $290 from 17 analysts, with a range of $217 to $337. Market data shows a higher consensus of $292.06 from 18 analysts, with a range of $230 to $349. The $349 high appears out of line with the most recent named targets.

Against the $280.56 close, the $289.06 consensus target suggests potential upside of about 3.0%.

What Are Wall Street Analysts Saying?

Market data gives a Hold consensus, with nine Buy, six Hold and three Sell ratings. The second data set shows nine Buy or Strong Buy, five Hold, two Sell and one Strong Sell.

Recent targets have mostly risen. On 9 October 2026 Morgan Stanley raised its target from $330 to $337 with an Overweight rating. Barclays moved from $270 to $281 on 7 October, TD Cowen from $292 to $300 and UBS from $260 to $270 on 5 October, and Wells Fargo initiated at Overweight with $301 on 2 October. Deutsche Bank downgraded to Hold on 19 August with a $270 target. In July, Bank of America (Underperform) held $230 and JPMorgan (Underweight) $250.

What Could Help the Stock Reach the Price Target?

Market data reports second-quarter earnings per share of $2.99 against $2.91 expected, and revenue of $1.71 billion against $1.68 billion, on 22 July 2026. A continued earnings beat could help sentiment.

Higher trading volumes in interest rate, equity and commodity futures, driven by market volatility, tend to lift exchange revenue. The run of October target increases suggests analysts are warming to that outlook.

What Could Prevent the Stock Reaching the Target?

The stock still trades near the consensus, leaving a modest margin. Bank of America and JPMorgan hold sub-$250 targets with negative ratings, and the second data set's low is $217.

Lower volatility, regulatory change, competition from other venues or reduced interest-rate trading could weigh on volumes. Analysts who downgraded in August did so on valuation, and rising targets may already be reflected in the price.

What Should Investors Watch Next?

Items to watch include monthly volume data, further target revisions and whether Hold-rated brokers move their ratings.

CME's October Target Raises Meet a Share Price Already Near Consensus

CME closed at $280.56 on 9 October 2026, with the $289.06 mean target only about 3.0% higher, so the stock still trades near the consensus, leaving a modest margin. A run of October raises from Morgan Stanley, Barclays, TD Cowen and UBS suggests analysts are warming to the volume outlook, yet Bank of America and JPMorgan hold sub-$250 targets with negative ratings and the second data set's low is $217. Market data shows second-quarter earnings per share of $2.99 against $2.91 expected.